Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Avonex

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.

Biogen grows in Q2, but Spinraza performance a concern

Biogen grows in Q2, but Spinraza performance a concern

The performance was thanks largely to its under-pressure multiple sclerosis (MS) franchise, where combined sales of Tecfidera, Avonex, Plegridy and Tysabri totalled $2.2bn.

Celgene hopes for second time lucky for ozanimod FDA filing

Celgene hopes for second time lucky for ozanimod FDA filing The new submission is based on the SUNBEAM study, a phase 3 trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod against weekly Avonex, current standard of ... It also pooled data from RADIANCE part B, another phase 3

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding Teva’s Copaxone, Biogen’s Avonex and Merck Serono’s Rebif have all been accepted for routine use on the NHS after the companies agreed to lower their prices – in addition

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug The efficacy of the drug had been demonstrated by two phase III trials comparing it to Biogen’s injectable interferon beta therapy Avonex, said Alles, who said the company “remains confident”

The good, the bad and the ugly

The good, the bad and the ugly Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...
GSK Steve Yancey
The long and winding road to asthma breakthroughs
Respiratory biologics are booming thanks to scientists who refused to be derailed by early research setbacks...
Nov cover
Combining hard technology with human skills
Chris Ross explores why pharma’s multichannel maturity isn’t just about hard technology – success depends on ‘human’ enablers...

Infographics